All lobbying filings

THE HEALTH EQUITY STRATEGIES GROUP, LLC

THE HEALTH EQUITY STRATEGIES GROUP, LLC filed a Q3 report for TRAVERE THERAPEUTICS on November 20, 2025, reporting $16,000 in lobbying income.

Lobbying for TRAVERE THERAPEUTICS · Pharmaceutical company

All filings by THE HEALTH EQUITY STRATEGIES GROUP, LLC · Everything TRAVERE THERAPEUTICS has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Nov 20, 2025

Income

$16,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 1

HOUSE OF REPRESENTATIVES

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Health Issues

Rare kidney disease

Medical/Disease Research/Clinical Labs

Rare kidney disease

Medicare/Medicaid

Rare kidney disease

Pharmacy

Rare kidney disease

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.